Table 1.
Total | Final Snellen VA ⩽20/40 | Final Snellen VA >20/40 | p | p c | OR (95% CI)c | |
---|---|---|---|---|---|---|
Study subjects [n, eyes] | 37 (37) | 27 (27) | 10 (10) | – | – | – |
Onset age (mean ± SD, years) | 38.7 ± 14.8 | 42.2 ± 14.6 | 29.1 ± 11.2 | 0.017 a | 0.120 | 0.90 (0.79–1.03) |
BMI (mean ± SD, kg/m2) | 24.2 ± 4.2 | 25.2 ± 4.2 | 21.7 ± 3.0 | 0.014 a | 0.166 | 0.75 (0.49–1.13) |
Gender (female, n, %) | 26 (70.3%) | 19 (70.4%) | 7 (70.0%) | >0.999b | –d | – |
Affected eye (bilateral, n, %) | 18 (48.6%) | 16 (59.3%) | 2 (20.0%) | 0.062b | 0.096 | 0.06 (0.00–1.64) |
Serum AQP4-antibody (positive, n, %) | 20 (54.1%) | 15 (55.6%) | 5 (50.0%) | >0.999b | 0.051 | 0.01 (0.00–1.01) |
Serum MOG-antibody status (n, %) | ||||||
Positive | 1 (2.7%) | 0 (0.0%) | 1 (10.0%) | |||
Negative | 23 (62.2%) | 15 (55.6%) | 8 (80.0%) | 0.053b | – | – |
Unknown | 13 (35.1%) | 12 (44.4%) | 1 (10.0%) | |||
Orbital MRI lesion (n, %) | ||||||
Retrobulbar | 29 (78.4%) | 20 (74.1%) | 9 (90.0%) | 0.404b | – | – |
Canalicular | 15 (40.5%) | 12 (44.4%) | 3 (30.0%) | 0.481b | – | – |
Intracranial | 10 (27.0%) | 8 (29.6%) | 2 (20.0%) | 0.694b | – | – |
Chiasmal involvement | 4 (10.8%) | 4 (14.8%) | 0 (0.0%) | 0.557b | – | – |
Longitudinally extensive optic nerve lesion | 33 (89.2%) | 24 (88.9%) | 9 (90.0%) | >0.999b | – | – |
VA at onset (logMAR, mean ± SD) | 3.4 ± 1.5 | 3.8 ± 1.4 | 2.5 ± 1.4 | 0.021 a | –d | – |
Onset to PE window (mean ± SD, days) | 27.2 ± 12.7 | 29.1 ± 13.0 | 22.4 ± 11.1 | 0.139a | 0.038 | 0.80 (0.64–0.99) |
Mann–Whitney U test.
Fisher’s exact test.
Logistic regression test.
Removed at the last step by backward stepwise method.
Bold: p < 0.05.
CI, confidence interval; AQP4, aquaporin-4; BMI, body mass index; logMAR, log of the minimum angle of resolution; MOG, myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; OR, odds ratio; PE, plasma exchange; SD, standard deviation; VA, visual acuity.